ArticleBreast cancer research and treatment2015
Deleterious BRCA1/2 mutations in an urban population of Black women.
Article in Breast cancer research and treatment, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Interventions to Improve Breast Screening Uptake for Black African Women in High Income Countries: A Systematic Review.Journal of racial and ethnic health disparities · 2026Review
- Hereditary ovarian cancer in women with African ancestry: a scoping review.Familial cancer · 2026Article
- Racial Disparities in Breast Cancer Genetic Testing May be Mitigated by Counseling.Annals of surgical oncology · 2024Article
- Germline sequence variants contributing to cancer susceptibility in South African breast cancer patients of African ancestry.Scientific reports · 2022Article
- New Insights Into c.815_824dup Pathogenic Variant ofFrontiers in oncology · 2021Review
- Molecular and Cellular Factors Associated with Racial Disparity in Breast Cancer.International journal of molecular sciences · 2020Review
- BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry.Human mutation · 2019Article
- Racial/Ethnic Disparities in BRCA Counseling and Testing: a Narrative Review.Journal of racial and ethnic health disparities · 2019Review
- Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.JCO precision oncology · 2018Article
- A state-wide initiative to promote genetic testing in an underserved population.Cancer medicine · 2017Article
- Predictors of BRCA1/2 genetic testing among Black women with breast cancer: a population-based study.Cancer medicine · 2017Article
- Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Article
- Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?Current treatment options in oncology · 2016Review
- Differences in Uptake of Risk Reduction Strategies Among Underserved Populations.EBioMedicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 1 country.
Funding
Abstract
Information on the prevalence of deleterious BRCA1 and BRCA2 (BRCA1/2) mutations in clinic-based populations of Black women is limited. In order to address this gap, we performed a retrospective study to determine the prevalence of deleterious BRCA1/2 mutations, predictors of having a mutation, and acceptance of risk-reducing surgeries in Black women. In an urban unselected clinic-based population, we evaluated 211 self-identified Black women who underwent genetic counseling for hereditary breast-ovarian cancer syndrome. BRCA1/2 mutations were identified in 13.4% of the participants who received genetic testing. Younger age at diagnosis, higher BRCAPRO score, significant family history, and diagnosis of triple-negative breast cancer were associated with identification of a BRCA1/2 mutation. Of the affected patients found to have a deleterious mutation, almost half underwent prophylactic measures. In our study population, 1 in 7 Black women who underwent genetic testing harbored a deleterious BRCA1/2 mutation independent of age at diagnosis or family history.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.